InvestorsHub Logo
Followers 30
Posts 2778
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Friday, 02/16/2018 3:40:48 PM

Friday, February 16, 2018 3:40:48 PM

Post# of 108
The CEO said they are in talks with Novartis and a range of combo* trials with ADU-S100 could start. He also said they might drop the systemic version. The PhI mono data shows the MTD has not yet been reached and no dose-limiting toxicities have been observed so far. They plan to complete the dose escalation portion in the H2 of this year. Once this happens they will report the results and also discuss the preliminary observations from the ongoing combo trial with PDR001 (anti-PD1).

*The first will be this